A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and clozapine in schizophrenic patients who are resistant and/or intolerant to antipsychotic treatment

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Antipsychotic Agents; Clozapine; Ziprasidone

Criteria

Inclusion Criteria:

• CGI - S ≥4

• PANSS ≥ 80

• Inpatients or outpatients

Exclusion Criteria:

• Patients with a history of myeloproliferative diseases, history of granulocytopenia, agranulocytosis due to a drug

• Diagnosis of substance dependence within previous 3 months using DSM-IV criteria

• History of seizure

• Organic mental disease, including mental retardation or epilepsy